|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:ATCCode
|
N05BA02
|
|
gptkbp:brand
|
gptkb:Librium
|
|
gptkbp:CASNumber
|
58-25-3
|
|
gptkbp:chemicalClass
|
1,4-benzodiazepine
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
severe respiratory insufficiency
sleep apnea syndrome
severe hepatic insufficiency
|
|
gptkbp:developedBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:discoveredBy
|
gptkb:Leo_Sternbach
|
|
gptkbp:discoveredIn
|
1957
|
|
gptkbp:eliminationHalfLife
|
5-30 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C16H14ClN3O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Chlordiazepoxide
|
|
gptkbp:IUPACName
|
gptkb:7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-one
|
|
gptkbp:KEGGID
|
D00297
|
|
gptkbp:legalStatus
|
gptkb:Schedule_IV
prescription only
|
|
gptkbp:legalStatusAU
|
S4
|
|
gptkbp:legalStatusCA
|
gptkb:Schedule_IV
|
|
gptkbp:legalStatusUK
|
Class C
|
|
gptkbp:marketedAs
|
1960
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor positive allosteric modulator
|
|
gptkbp:MedlinePlusID
|
a682078
|
|
gptkbp:meltingPoint
|
232-233°C
|
|
gptkbp:metabolism
|
gptkb:desmethylchlordiazepoxide
gptkb:nordiazepam
gptkb:oxazepam
demoxepam
|
|
gptkbp:pregnancyCategory
|
C
D (US)
|
|
gptkbp:proteinBinding
|
96%
|
|
gptkbp:PubChem_CID
|
2726
CHEMBL651
2624
DB00475
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
confusion
drowsiness
ataxia
dependence
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:UNII
|
S8VZ499Y41
|
|
gptkbp:usedFor
|
gptkb:alcohol_withdrawal_syndrome
anxiety disorders
preoperative sedation
|
|
gptkbp:bfsParent
|
gptkb:Benzodiazepines
gptkb:D07917
|
|
gptkbp:bfsLayer
|
6
|